Anebulo Pharmaceuticals Q2 EPS $(0.11) Misses $(0.10) Estimate
Portfolio Pulse from Happy Mohamed
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported Q2 EPS of $(0.11), missing the consensus estimate of $(0.10) by 10%. This represents a 26.67% improvement over the $(0.15) per share loss from the same quarter last year.
February 13, 2024 | 9:44 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Anebulo Pharmaceuticals reported a Q2 EPS of $(0.11), missing estimates by 10% but improved 26.67% YOY.
Missing the EPS estimate could lead to short-term negative sentiment among investors, despite the year-over-year improvement. The miss, although slight, may cause concern about the company's ability to meet expectations, potentially impacting its stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100